secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001437749-24-003924
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen reports narrower net loss of $6.3M in fiscal Q3; fasedienol trials on track
--------------------------------------------------------------------------------

- Net loss $6.3M vs $9.8M YoY; cash $126.6M at Dec 31, 2023.
- R&D expense $4.5M, down from $6.9M on lower clinical costs.
- G&A expense $3.8M, up from $3.1M on compensation.
- PALISADE-3 fasedienol trial for SAD initiation expected 1H 2024; PALISADE-4 in 2H 2024.
- Preparations underway for itruvone Phase 2B in MDD and PH80 Phase 2B in vasomotor symptoms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774924003924/0001437749-24-003924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774924003924/vtgn20240213_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-003924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer